Pioglitazone in triple therapy

The licence for Actos (pioglitazone) has been extended to include triple oral therapy in combination with metformin and a sulphonylurea in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Previously, Actos was licensed only as monotherapy or as dual therapy in combination with either metformin or a sulphonylurea.

The recommended dose of pioglitazone is the same whether used in montherapy or dual or triple combination therapy. Treatment should be started at 15-30mg once daily increasing to 45mg once daily if necessary in combination with metformin and/or a sulphonylurea.

Common adverse effects associated with triple therapy include weight gain, increased creatine phosphokinase, arthralgia and hypoglycaemia.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...